Action ABIO ARCA BIOPHARMA, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués ARCA biopharma, Inc.

Actions

ABIO

US00211Y5069

Temps réel estimé Cboe BZX
Autres places de cotation
 20:47:21 17/07/2024 		Varia. 5j. Varia. 1 janv.
3,53 USD -0,56 % Graphique intraday de ARCA biopharma, Inc. +1,45 % +105,29 %
25/04 ARCA biopharma, Inc. déclare ses résultats pour le premier trimestre clos le 31 mars 2024 CI
04/04 ARCA biopharma, Inc. annonce des changements au sein de sa direction CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka
PR
ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
BU
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO
PR
ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
BU
Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka
PR
ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders
BU
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
AQ
ARCA biopharma Announces 2023 Financial Results
AQ
ARCA biopharma Announces Third Quarter 2023 Financial Results
AQ
ARCA biopharma announces Second Quarter 2023 Financial Results
AQ
ARCA biopharma Announces Second Quarter 2023 Financial Results
AQ
ARCA biopharma : Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options - Form 8-K
PU
ARCA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
ARCA biopharma Announces First Quarter 2023 Financial Results
AQ
ARCA BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
AQ
ARCA biopharma : Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options - Form 8-K
PU
ARCA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
ARCA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ABIO
  4. Actualités ARCA biopharma, Inc.
  5. Communiqués